Mesenchymal Stem Cells With Pharmacological Combinations Necessary to Maximize Retinal Photoreceptor, Outer and Inner...

Area of Science:

• Ophthalmology
• Regenerative Medicine
• Neuroscience

Background:

• Retinal diseases are increasing, necessitating personalized neuroprotection.
• Mesenchymal stem cells (MSCs) show paracrine neuroprotective effects.
• Clinical application of MSCs often avoids transplantation.

Purpose of the Study:

• To evaluate MSC-mediated photoreceptor rescue.
• To assess enhancement of MSC therapy using nicotinamide (NIC), vasoactive intestinal peptide (VIP), and retinoic acid (ATRA).
• To explore personalized treatment optimization based on retinal damage severity.

Main Methods:

• Adipose-derived MSCs were co-cultured with degenerating neuroretina explants for 6 days.
• Drugs (VIP, NIC, ATRA) were applied individually and in combination.
• Photoreceptor recovery and retinal layer structures (ILM, ONL, INL) were assessed via Toluidine, Rhodopsin immunofluorescence, and DAPI staining.

Main Results:

• MSCs alone improved photoreceptor and retinal layer recovery compared to controls.
• Combined VIP, NIC, and ATRA showed greater improvement than individual drugs.
• NIC was the most effective single treatment; VIP and NIC combination preserved retinal structure best.
• No treatment fully restored original retinal structure.

Conclusions:

• Personalized strategies combining MSCs with specific drugs significantly enhance retinal neuroprotection.
• Treatment efficacy is tailored to the degree of retinal damage.
• Individualized approaches are crucial for managing retinal diseases effectively.